|
週次 |
日期 |
單元主題 |
|
第1週 |
2/21 |
Master Day 2 PM @舊館 R213 |
|
第2週 |
2/28 |
和平紀念日 |
|
第3週 |
3/07 |
Master Day 2 PM @舊館 R213 |
|
第4週 |
3/14 |
Master Day 2 PM @舊館 R213 |
|
第5週 |
3/21 |
論文研讀與預講 |
|
第6週 |
3/28 |
論文研讀與預講 |
|
第7週 |
4/04 |
春假 |
|
第8週 |
4/11 |
林昕芃
RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors. Clin Cancer Res. 22: 1499-1509. (2016)
林庭瑋
Exosomes Derived From Natural Killer Cells Exert Therapeutic Effect in Melanoma. Theranostics. 7(10):2732-2745 (2017) |
|
第9週 |
4/18 |
黃鈞暘
Loss of ADAR1 in tumours overcomes resistance to immune checkpoint blockade. Nature 565, 43-48 (2019)
李佳蓉
NF-kB c-Rel Is Crucial for the Regulatory T Cell Immune Checkpoint in Cancer. Cell. 170(6): 1096-1108 (2017) |
|
第10週 |
4/25 |
黃家星
Anti-cancer Activity of Novel TM4SF5-Targeting Antibodies through TM4SF5 Neutralization and Immune Cell-Mediated Cytotoxicity. Theranostics. 11;7(3):594-613 (2017)
張法理
Precision glycocalyx editing as a strategy for cancer immunotherapy. PNAS. 113(37): 10304-9 (2016) |
|
第11週 |
5/02 |
吳靜宜
IL10 Release upon PD-1 Blockade Sustains Immunosuppression in Ovarian Cancer. Cancer Res. 77:6667-6678 (2017)
王加恩
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors. Science. 359: 91-97 (2018) |
|
第12週 |
5/09 |
黃政睿
Metabolic rewiring of macrophages by CpG potentiates clearance of cancer cells and overcomes tumor-expressed CD47−mediated ‘don’t-eat-me’ signal. Nature Immunology 20: 265–275 (2019)
杜毓凡
Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell. 173, 1439–1453 (2018)
Matteo Hofmann
Design of split superantigen fusion proteins for cancer immunotherapy |